Stephen D. Wolpe

Biography

 Dr. Wolpe was one of the discoverers of the chemokine family (MIP-1alpha, MIP-1beta and MIP-2) and wrote a seminal review establishing this superfamily of inflammatory proteins. After his post-doctoral work at Rockefeller University, he joined Genetics Institute (now part of Pfizer) where he was project leader for hematopoetic and intestinal stem cell projects. Following his time at Genetics Institute, Dr. Wolpe held a variety of senior positions at the Wellstat Group of Companies (a privately-held group of companies started by the founder of Amgen, Applied Biosystems and IGEN/Bioveris) where he continued his work on stem cells as well as leading research teams developing drugs and vaccines for diabetes, inflammatory disease and cancer. He was instrumental in developing a diabetes drug, a novel insulin sensitizer, that successfully concluded Ph2 clinical trials and was licensed to Sanofi for $350MM. Dr. Wolpe also worked at a senior level on business development, intellectual property assessment and licensing for the Wellstat Companies. Prior to joining Targazyme as Chief Scientific Officer, Dr. Wolpe worked as an independent biotech consultant for a wide variety of technologies and companies in the US, China and Israel. He is an author on over 25 publications in the scientific literature and an inventor on over 40 patents.  

Research Interest

 Drug Development and Vaccines for Diabetes